Dec 6, 2024
3:30pm - 4:00pm
Hynes, Level 1, Room 111
Avi Schroeder1,Orly Shyaderman1,Ibrahim Knani1,Mohammed Alyan1,Jeny Shklover1,Ravit Abel1,2,Shanny Ackerman1,Noga Sharf-Pauker1,2,Omer Kfir1
Technion-Israel Institute of Technology1,Technion–Israel Institute of Technology2
Avi Schroeder1,Orly Shyaderman1,Ibrahim Knani1,Mohammed Alyan1,Jeny Shklover1,Ravit Abel1,2,Shanny Ackerman1,Noga Sharf-Pauker1,2,Omer Kfir1
Technion-Israel Institute of Technology1,Technion–Israel Institute of Technology2
Nanotechnology holds numerous potential benefits for treating and diagnosing disease, including the ability to transport complex therapeutic cargoes and target specific tissues. 2D-materials, embedded inside therapeutic nanoparticles, have the ability to enhance the therapeutic potency. Specifically, 2D materials loaded into liposomes sensitize the tumor to treatment, improving patient-specific therapeutic activity. The talk will also describe how the liposomal lipid composition affects its ability to internalize into triple-negative breast cancer cells, looking at the different molecular features, and how these can be leveraged to induce an anti-tumor immune response.<br/>The evolution of drug delivery systems into synthetic cells, programmed nanoparticles with an autonomous syn-bio capacity to synthesize diagnostic and therapeutic proteins inside the body, and their promise for treating disease, will be discussed.<br/>Integrating inorganic 2D materials into drug delivery systems enable new therapeutic capabilities.<br/>References:<br/>1. Synthetic cells with self-activating optogenetic proteins communicate with natural cells, Adir et al. Nature Communications, 2022, 13, 2328<br/>2. Implanted synthetic cells trigger tissue angiogenesis through de novo production of recombinant growth factors, Chen et al., PNAS, 2022, 119 (38) e2207525119<br/><br/>ACKNOWLEDGMENT: This work has been funded by the Horizon European EIC Patfinder Project "PERSEUS" [grant number 101099423] and European Union (ERC, NutriCells, 101113408).